Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
The purpose of this study is to demonstrate that CHF 1535 NEXT DPI® is non-inferior to the corresponding dose of CHF 1535 pMDI and superior to marketed beclomethasone DPI 100 µg in terms of average pre-dose morning Peak Expiratory Flow (PEF) in asthmatic adult patients.
Epistemonikos ID: 3d424d06bd85f95c5710d927a4fb574d66d918b7
First added on: May 06, 2024